ADMA Stock Risk & Deep Value Analysis
ADMA Biologics Inc
DVR Score
out of 10
What You Need to Know About ADMA Stock
We analyzed ADMA Biologics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ADMA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
ADMA Risk Analysis & Red Flags
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Upcoming Risk Events
- 📅
Lower-than-expected Q1 2026 earnings or cautious FY2026 guidance (Q2 2026)
- 📅
Increased competitive pressure or pricing erosion from larger players
- 📅
Slower-than-anticipated plasma center ramp-ups or collection volume growth
- 📅
Supply chain disruptions impacting plasma fractionation
Unlock ADMA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
ADMA Biologics is a compelling high-growth investment positioned to become a significant leader in the IVIG market. Its successful vertical integration strategy, leading to increasing profitability and substantial revenue growth, combined with a differentiated product (ASCENIV) and expanding plasma network, provides a durable competitive advantage. The company is executing effectively on its vision to capitalize on an undersupplied market, making it ripe for significant re-rating and 10x potential within 3-5 years.
Is ADMA Stock Undervalued?
Unlock the full AI analysis for ADMA
Get the complete DVR score, risk analysis, and more
ADMA Price Targets & Strategy
12-Month Target
$28.50
Bull Case
$35.00
Bear Case
$18.00
Entry Strategy
Dollar-cost average on pullbacks to the $22-$25 range. Initiate partial position now, scaling in on any volatility.
Exit Strategy
Take initial profits at $30-$32, re-evaluate holding strength at $40+. Maintain a stop-loss at $19.50.
Portfolio Allocation
7-10% for aggressive risk tolerance; 3-5% for moderate risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does ADMA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
The moat is strengthening due to increasing vertical integration, which reduces external supply reliance and costs, coupled with a differentiated product and the high regulatory and capital intensity of the plasma industry. This makes it difficult for new entrants to compete effectively.
Moat Erosion Risks
- •Aggressive pricing strategies from larger, established competitors
- •Emergence of a superior therapeutic alternative to IVIG
- •Regulatory changes impacting plasma collection or product approval processes
ADMA Competitive Moat Analysis
Sign up to see competitive advantages
ADMA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish
Institutional Sentiment
Positive
Insider Activity (Form 4)
Limited insider selling, with some opportunistic buying observed on minor dips over the last 6 months, signaling confidence.
Options Flow
Consistent elevated call option volume, particularly for mid-term expiries, indicating bullish institutional positioning.
Earnings Intelligence
Next Earnings
2026-04-29 (Estimated)
Surprise Probability
High
Historical Earnings Pattern
Typically rallies 8-15% on earnings beats accompanied by strong guidance. Tends to consolidate or experience minor pullbacks on in-line results if future guidance is conservative.
Key Metrics to Watch
Competitive Position
Top Competitor
CSL
Market Share Trend
Gaining
Valuation vs Peers
Trading at a premium on EV/Sales (reflecting high growth potential) but potentially undervalued on future earnings multiples compared to larger, slower-growth peers like CSL and Grifols, given its growth trajectory and margin expansion capabilities.
Competitive Advantages
- •Vertical integration of plasma collection, fractionation, and commercialization
- •Differentiated product profile (ASCENIV with specific indications)
- •Operational efficiency improvements driving margin expansion
- •Strategic focus on underserved IVIG market segments
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ADMA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April 2026)
- •Announcement of 2-3 new plasma center openings in Q2 2026
- •Updated FY2026 revenue and margin guidance
Medium-Term (6-18 months)
- •Continued significant increases in plasma collection volumes and capacity utilization (H2 2026 - H1 2027)
- •Potential strategic partnership for international market expansion (late 2026)
- •Completion of debt refinancing to further reduce interest expenses and enhance flexibility (early 2027)
Long-Term (18+ months)
- •Achievement of significant market share in the U.S. IVIG market (2028-2029)
- •Potential approval for additional indications for ASCENIV or new product pipeline advancement (2029+)
- •Becoming a key player in the global plasma-derived therapeutics market (2030+)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ADMA?
- ✓
Acceleration in gross margin expansion and sustained positive operating cash flow
- ✓
Consistent reporting of new plasma center openings and increasing plasma collection volumes
- ✓
Successful execution of debt reduction or refinancing efforts
Bull Case Analysis
See what could go right with Premium
Competing with ADMA
See how ADMA Biologics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
ADMA Biologics Inc ADMA | — | 9.3 | — | — | — | — |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for ADMA Biologics Inc (ADMA)?
As of March 15, 2026, ADMA Biologics Inc has a DVR Score of 9.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for ADMA stock?
Our analysis rates ADMA Biologics Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the ADMA DVR analysis updated?
Our AI-powered analysis of ADMA Biologics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ADMA (ADMA Biologics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.